Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Regulations Restricting the Sale and Distribution of Cigarettes and Smokeless Tobacco To Protect Children and Adolescents, 20923-20924 [2013-08034]
Download as PDF
20923
Federal Register / Vol. 78, No. 67 / Monday, April 8, 2013 / Notices
Dated: April 1, 2013.
Ron A. Otten,
Director, Office of Scientific Integrity, Office
of the Associate Director for Science, Office
of the Director, Centers for Disease Control
and Prevention.
[FR Doc. 2013–08051 Filed 4–5–13; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Daniel Gittleson, Office of Information
Management, Food and Drug
Administration, 1350 Piccard Dr., PI50–
400B, Rockville, MD 20850, 301–796–
5156, daniel.gittleson@fda.hhs.gov.
In
compliance with 44 U.S.C. 3507, FDA
has submitted the following proposed
collection of information to OMB for
review and clearance.
[Docket No. FDA–2012–N–0977]
Agency Information Collection
Activities; Submission for Office of
Management and Budget Review;
Comment Request; Regulations
Restricting the Sale and Distribution of
Cigarettes and Smokeless Tobacco To
Protect Children and Adolescents
Food and Drug Administration,
HHS.
ACTION:
FOR FURTHER INFORMATION CONTACT:
SUPPLEMENTARY INFORMATION:
Food and Drug Administration
AGENCY:
OMB control number 0910–0312. Also
include the FDA docket number found
in brackets in the heading of this
document.
Notice.
The Food and Drug
Administration (FDA) is announcing
that a proposed collection of
information has been submitted to the
Office of Management and Budget
(OMB) for review and clearance under
the Paperwork Reduction Act of 1995.
DATES: Fax written comments on the
collection of information by May 8,
2013.
SUMMARY:
To ensure that comments on
the information collection are received,
OMB recommends that written
comments be faxed to the Office of
Information and Regulatory Affairs,
OMB, Attn: FDA Desk Officer, FAX:
202–395–7285, or emailed to
oira_submission@omb.eop.gov. All
comments should be identified with the
ADDRESSES:
Regulations Restricting the Sale and
Distribution of Cigarettes and
Smokeless Tobacco To Protect Children
and Adolescents—21 CFR Part 1140
(OMB Control Number 0910–0312)—
Revision
This is a request for an extension of
OMB approval of the information
collection requirements contained in
FDA’s regulations for cigarettes and
smokeless tobacco containing nicotine.
The regulations that are codified at 21
CFR part 1140 (previously codified at 21
CFR part 897) are authorized by section
102 of the Family Smoking Prevention
and Tobacco Control Act (Tobacco
Control Act) (Pub. L. 111–31). Section
102 of the Tobacco Control Act required
FDA to publish a final rule regarding
cigarettes and smokeless tobacco
identical in its provisions to the
regulation issued by FDA in 1996 (61 FR
44396, August 28, 1996), with certain
specified exceptions—which included
striking subpart C (with § 897.24) and
§ 897.32(c) from the reissued rule
(section 102(a)(2)(B). The reissued final
rule was published in the Federal
Register on March 19, 2010 (75 FR
13225).
This collection includes reporting
information requirements for § 1140.30,
which directs persons to notify FDA if
they intend to use a form of advertising
that is not addressed in the regulations.
Disclosure requirements for § 1140.32
state that the advertising must use black
text on a white background, but that this
particular requirement does not apply to
adult newspapers, magazines,
periodicals, or other publications.
Recordkeeping requirements under
§ 1140.32 indicate that competent and
reliable survey evidence is required to
determine whether a particular
publication is an ‘‘adult’’ publication.
The requirements are as follows:
• Reporting—§ 1140.30 directs
persons to notify FDA if they intend to
use a form of advertising that is not
described in § 1140.30(a)(1).
• Disclosure—§ 1140.32 requires
firms to use black text on white
backgrounds in labeling and advertising.
• Recordkeeping—§ 1140.32 indicates
that firms advertising in ‘‘adult’’
magazines or publications may need
survey evidence demonstrating that the
publication meets the criteria for an
‘‘adult’’ publication.
For the disclosure and recordkeeping
requirements under § 1140.32, FDA has
decided to use its discretionary
enforcement and has placed
placeholders of 1 burden hour for
disclosure and 1 burden hour for
reporting because FDA does not intend
to enforce the requirements for this
section for the next 3 years.
In the Federal Register of September
28, 2012 (77 FR 59622), FDA published
a 60-day notice requesting public
comment on the proposed collection of
information. No comments were
received.
FDA estimates the burden of this
collection of information as follows:
TABLE 1—ESTIMATED ANNUAL REPORTING BURDEN 1
21 CFR Section
Number of
respondents
Number of
responses per
respondent
Total annual
responses
Average
burden per
response
Total hours
1140.30 (Scope of permissible forms of labeling and advertising) ...........................................................................
300
1
300
1
300
1 There
are no capital costs or operating and maintenance costs associated with this collection of information.
mstockstill on DSK4VPTVN1PROD with NOTICES
TABLE 2—ESTIMATED ANNUAL RECORDKEEPING BURDEN 1
21 CFR Section
Number of
recordkeepers
Number of
records per
recordkeeper
Total annual
records
Average
burden per
recordkeeping
Total hours
1140.32 (Format and content requirements for labeling
and advertising) ................................................................
1
1
1
1
1
1 There
are no capital costs or operating and maintenance costs associated with this collection of information.
VerDate Mar<15>2010
20:02 Apr 05, 2013
Jkt 229001
PO 00000
Frm 00041
Fmt 4703
Sfmt 4703
E:\FR\FM\08APN1.SGM
08APN1
20924
Federal Register / Vol. 78, No. 67 / Monday, April 8, 2013 / Notices
TABLE 3—ESTIMATED ANNUAL THIRD-PARTY DISCLOSURE BURDEN 1
21 CFR Section
Number of
respondents
Number of
disclosures
per
respondent
Total annual
disclosures
Average
burden per
disclosure
Total hours
1140.32 ................................................................................
1
1
1
1
1
mstockstill on DSK4VPTVN1PROD with NOTICES
1 There
are no capital costs or operating and maintenance costs associated with this collection of information.
The burden hour estimates for this
collection of information were based on
industry-prepared data and information
regarding pharmaceutical advertising
and cigarette and smokeless tobacco
product advertising expenditures. The
burden collection does not include
reporting burdens associated with
providing established names on labels
and statements of intended use because
section 102 of the Tobacco Control Act
required that these provisions be struck
from the reissued final rule (previously
included in §§ 897.24 and 897.32(c)).
Section 1140.30 requires
manufacturers, distributors, and
retailers to observe certain format and
content requirements for labeling and
advertising, and requires manufacturers,
distributors, and retailers to notify FDA
if they intend to use an advertising
medium that is not listed in the
regulations. The concept of permitted
advertising in § 1140.30 is sufficiently
broad to encompass most forms of
advertising. FDA estimates that
approximately 300 respondents will
submit an annual notice of alternative
advertising, and the Agency has
estimated it should take 1 hour to
provide such notice.
For the recordkeeping and disclosure
requirements, § 1140.32 requires
competent and reliable survey evidence
to establish whether a newspaper,
magazine, periodical, or other
publication qualifies as an ‘‘adult’’
publication. Section 1140.32 also
requires the use of a black text on a
white background for labeling and
advertising. The respondent and hourly
burden for recordkeeping and disclosure
under this section (2 burden hours total)
reflect placeholders for the number of
manufacturers who would keep records
under this section.
During the next 3 years, FDA does not
intend to enforce the recordkeeping and
disclosure requirements of § 1140.32
and has revised the burden to act as a
placeholder in the event FDA exercises
its authority to enforce the requirements
of this section in the future.
FDA estimates that the total time
required for this collection of
information is 302 hours.
VerDate Mar<15>2010
20:02 Apr 05, 2013
Jkt 229001
Dated: April 2, 2013.
Leslie Kux,
Assistant Commissioner for Policy.
[FR Doc. 2013–08034 Filed 4–5–13; 8:45 am]
BILLING CODE 4160–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2013–N–0248]
Center for Biologics Evaluation and
Research eSubmitter Pilot Evaluation
Program for Investigational New Drug
Applications
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
The Food and Drug
Administration’s (FDA’s) Center for
Biologics Evaluation and Research
(CBER) is announcing an invitation to
sponsors of investigational new drug
(IND) applications to participate in a
pilot evaluation program for CBER’s
eSubmitter Program (eSubmitter).
CBER’s eSubmitter is a computerassisted automated program that has
been customized to facilitate the
creation of IND applications in
electronic format, including a template
specifically for IND applications related
to antivenom drugs/antivenins.
Participation in the pilot program is
open to sponsors that submit IND
applications to the Office of Blood
Research and Review, the Office of
Cellular, Tissue and Gene Therapy, or
the Office of Vaccines Research and
Review in CBER. CBER will only accept
participation from up to nine sponsors.
The pilot program is intended to
provide industry and CBER regulatory
review staff with an opportunity to
evaluate the eSubmitter system and
determine if it facilitates the IND
submission process. The purpose of this
notice is to invite sponsors of IND
applications to contact CBER for more
information if they are interested in
participating in this pilot program.
DATES: Submit an electronic request for
participation in this program by July 8,
2013.
SUMMARY:
PO 00000
Frm 00042
Fmt 4703
Sfmt 4703
If you are interested in
participating in this program, you
should submit an electronic request to
CBER_eSubmitter_program
@fda.hhs.gov.
FOR FURTHER INFORMATION CONTACT: Lore
Fields, Office of Blood Research and
Review, Center for Biologics Evaluation
and Research (HFM–375), Food and
Drug Administration, 1401 Rockville
Pike, suite 200N, Rockville, MD 20852–
1448, 301–827–6143, FAX: 301–827–
3534, email: lore.fields@fda.hhs.gov.
SUPPLEMENTARY INFORMATION:
ADDRESSES:
I. Background
CBER regulates certain biological
products and is committed to advancing
the public health through innovative
activities that help ensure the safety,
effectiveness, and timely delivery of
these products to patients. Further,
CBER seeks to continuously enhance
and update the efficiency and quality of
its regulatory review process and to
facilitate its interaction with
stakeholders by providing CBER staff
and industry with improved processes.
In support of this goal, CBER has
participated in FDA’s development of
eSubmitter to improve the process for
providing certain regulatory
submissions to FDA.
II. eSubmitter Pilot Evaluation Program
Expectations
The eSubmitter pilot evaluation
program is expected to last
approximately 6 months. During this
period of time, participants will
complete their IND application
submissions using the eSubmitter
template developed by FDA that has
been specifically designed for use by
IND sponsors. eSubmitter was
developed using the same criteria for
applications that are currently used in
the IND application review process at
CBER. To create the IND application,
the participant will enter the requested
information into the eSubmitter tool and
attach requested documents as an
Adobe document (pdf format). This
information will be saved onto a CD–
ROM by the sponsor and mailed to
CBER for review. Paper copies of
submissions will not be required. CBER
will review the information provided on
E:\FR\FM\08APN1.SGM
08APN1
Agencies
[Federal Register Volume 78, Number 67 (Monday, April 8, 2013)]
[Notices]
[Pages 20923-20924]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2013-08034]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2012-N-0977]
Agency Information Collection Activities; Submission for Office
of Management and Budget Review; Comment Request; Regulations
Restricting the Sale and Distribution of Cigarettes and Smokeless
Tobacco To Protect Children and Adolescents
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is announcing that a
proposed collection of information has been submitted to the Office of
Management and Budget (OMB) for review and clearance under the
Paperwork Reduction Act of 1995.
DATES: Fax written comments on the collection of information by May 8,
2013.
ADDRESSES: To ensure that comments on the information collection are
received, OMB recommends that written comments be faxed to the Office
of Information and Regulatory Affairs, OMB, Attn: FDA Desk Officer,
FAX: 202-395-7285, or emailed to oira_submission@omb.eop.gov. All
comments should be identified with the OMB control number 0910-0312.
Also include the FDA docket number found in brackets in the heading of
this document.
FOR FURTHER INFORMATION CONTACT: Daniel Gittleson, Office of
Information Management, Food and Drug Administration, 1350 Piccard Dr.,
PI50-400B, Rockville, MD 20850, 301-796-5156,
daniel.gittleson@fda.hhs.gov.
SUPPLEMENTARY INFORMATION: In compliance with 44 U.S.C. 3507, FDA has
submitted the following proposed collection of information to OMB for
review and clearance.
Regulations Restricting the Sale and Distribution of Cigarettes and
Smokeless Tobacco To Protect Children and Adolescents--21 CFR Part 1140
(OMB Control Number 0910-0312)--Revision
This is a request for an extension of OMB approval of the
information collection requirements contained in FDA's regulations for
cigarettes and smokeless tobacco containing nicotine. The regulations
that are codified at 21 CFR part 1140 (previously codified at 21 CFR
part 897) are authorized by section 102 of the Family Smoking
Prevention and Tobacco Control Act (Tobacco Control Act) (Pub. L. 111-
31). Section 102 of the Tobacco Control Act required FDA to publish a
final rule regarding cigarettes and smokeless tobacco identical in its
provisions to the regulation issued by FDA in 1996 (61 FR 44396, August
28, 1996), with certain specified exceptions--which included striking
subpart C (with Sec. 897.24) and Sec. 897.32(c) from the reissued
rule (section 102(a)(2)(B). The reissued final rule was published in
the Federal Register on March 19, 2010 (75 FR 13225).
This collection includes reporting information requirements for
Sec. 1140.30, which directs persons to notify FDA if they intend to
use a form of advertising that is not addressed in the regulations.
Disclosure requirements for Sec. 1140.32 state that the advertising
must use black text on a white background, but that this particular
requirement does not apply to adult newspapers, magazines, periodicals,
or other publications. Recordkeeping requirements under Sec. 1140.32
indicate that competent and reliable survey evidence is required to
determine whether a particular publication is an ``adult'' publication.
The requirements are as follows:
Reporting--Sec. 1140.30 directs persons to notify FDA if
they intend to use a form of advertising that is not described in Sec.
1140.30(a)(1).
Disclosure--Sec. 1140.32 requires firms to use black text
on white backgrounds in labeling and advertising.
Recordkeeping--Sec. 1140.32 indicates that firms
advertising in ``adult'' magazines or publications may need survey
evidence demonstrating that the publication meets the criteria for an
``adult'' publication.
For the disclosure and recordkeeping requirements under Sec.
1140.32, FDA has decided to use its discretionary enforcement and has
placed placeholders of 1 burden hour for disclosure and 1 burden hour
for reporting because FDA does not intend to enforce the requirements
for this section for the next 3 years.
In the Federal Register of September 28, 2012 (77 FR 59622), FDA
published a 60-day notice requesting public comment on the proposed
collection of information. No comments were received.
FDA estimates the burden of this collection of information as
follows:
Table 1--Estimated Annual Reporting Burden \1\
--------------------------------------------------------------------------------------------------------------------------------------------------------
Number of
21 CFR Section Number of responses per Total annual Average burden Total hours
respondents respondent responses per response
--------------------------------------------------------------------------------------------------------------------------------------------------------
1140.30 (Scope of permissible forms of labeling and advertising)... 300 1 300 1 300
--------------------------------------------------------------------------------------------------------------------------------------------------------
\1\ There are no capital costs or operating and maintenance costs associated with this collection of information.
Table 2--Estimated Annual Recordkeeping Burden \1\
--------------------------------------------------------------------------------------------------------------------------------------------------------
Number of Average burden
21 CFR Section Number of records per Total annual per Total hours
recordkeepers recordkeeper records recordkeeping
--------------------------------------------------------------------------------------------------------------------------------------------------------
1140.32 (Format and content requirements for labeling and 1 1 1 1 1
advertising)......................................................
--------------------------------------------------------------------------------------------------------------------------------------------------------
\1\ There are no capital costs or operating and maintenance costs associated with this collection of information.
[[Page 20924]]
Table 3--Estimated Annual Third-Party Disclosure Burden \1\
--------------------------------------------------------------------------------------------------------------------------------------------------------
Number of
21 CFR Section Number of disclosures per Total annual Average burden Total hours
respondents respondent disclosures per disclosure
--------------------------------------------------------------------------------------------------------------------------------------------------------
1140.32............................................................ 1 1 1 1 1
--------------------------------------------------------------------------------------------------------------------------------------------------------
\1\ There are no capital costs or operating and maintenance costs associated with this collection of information.
The burden hour estimates for this collection of information were
based on industry-prepared data and information regarding
pharmaceutical advertising and cigarette and smokeless tobacco product
advertising expenditures. The burden collection does not include
reporting burdens associated with providing established names on labels
and statements of intended use because section 102 of the Tobacco
Control Act required that these provisions be struck from the reissued
final rule (previously included in Sec. Sec. 897.24 and 897.32(c)).
Section 1140.30 requires manufacturers, distributors, and retailers
to observe certain format and content requirements for labeling and
advertising, and requires manufacturers, distributors, and retailers to
notify FDA if they intend to use an advertising medium that is not
listed in the regulations. The concept of permitted advertising in
Sec. 1140.30 is sufficiently broad to encompass most forms of
advertising. FDA estimates that approximately 300 respondents will
submit an annual notice of alternative advertising, and the Agency has
estimated it should take 1 hour to provide such notice.
For the recordkeeping and disclosure requirements, Sec. 1140.32
requires competent and reliable survey evidence to establish whether a
newspaper, magazine, periodical, or other publication qualifies as an
``adult'' publication. Section 1140.32 also requires the use of a black
text on a white background for labeling and advertising. The respondent
and hourly burden for recordkeeping and disclosure under this section
(2 burden hours total) reflect placeholders for the number of
manufacturers who would keep records under this section.
During the next 3 years, FDA does not intend to enforce the
recordkeeping and disclosure requirements of Sec. 1140.32 and has
revised the burden to act as a placeholder in the event FDA exercises
its authority to enforce the requirements of this section in the
future.
FDA estimates that the total time required for this collection of
information is 302 hours.
Dated: April 2, 2013.
Leslie Kux,
Assistant Commissioner for Policy.
[FR Doc. 2013-08034 Filed 4-5-13; 8:45 am]
BILLING CODE 4160-01-P